The metabolic process which fuels the growth of many cancers has its origins in normal brain growth finds a new study published in BioMed Central's open access journal Cancer & Metabolism. Using knock-out mice the study shows that interfering with Hexokinase-2 (Hk2), an enzyme integral to glucose metabolism, reduces the aggressiveness of medulloblastoma, the most common malignant brain tumor in children, and allows long term survival of mice.
Most cells only convert glucose to lactate in the absence of oxygen, for example, during a short burst of intensive exercise (anaerobic glycolysis). However rapidly dividing cells, including many cancer cells, convert glucose to lactate even in the presence of oxygen (aerobic glycolysis).
Researchers from the University of North Carolina have found that Hk2 switches on aerobic glycolysis in progenitor cells of the brain and in medulloblastoma. In the absence of Hk2, brain development was disordered. Additionally they found that deleting the Hk2 gene in mice genetically prone to develop medulloblastoma reduced the aggressiveness of the tumors, allowing long-term survival of the mice.
Dr. Timothy Gershon, who led this study, explained, "As long ago as 1924 Otto Warburg hypothesized that cancers use glycolysis to provide energy for growth even in the presence of oxygen. We found that glycolysis in the presence of oxygen is a developmental process that is co-opted in cancer to support malignant growth. We can now think about targeting this process in patients".
Open access publisher BioMed Central is proud to announce the launch of the Cancer & Metabolism . Professor Chi van Dang, co-Editor-in-Chief, commented that "It has become self-evident that metabolism and bioenergetics are regulated by cancer genes. Cancer & Metabolism is launched uniquely to fulfil the needs of a burgeoning field." Professor Michael Pollak, co-Editor-in-Chief, added that "The scope of Cancer & Metabolism will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."
BioMed Central: http://www.biomedcentral.com
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Pharmacology can get a bad rap in the press. Professors George Davey Smith and David Nutt fight the case for statins and SSRIs.
People who spend time watching fish swim in aquarium tanks could improve their physical and mental wellbeing, a study shows.
The chytrid fungus has wiped out populations of amphibians around the world. A type of the fungus infects only salamanders, and researchers have identified vulnerable areas in North America.
NPR's Melissa Block speaks with the AP's Brazil bureau chief Brad Brooks about the investigation, which found high levels of dangerous viruses in water venues for the 2016 Summer Olympics.
Unusual clinical trial in Guinea offers promise for stopping epidemic
Researchers say study suggests need to target black men for screening of prostate cancer, which is projected to become the UK’s most common cancer by 2030 Black men in England have twice the lifetime risk of both being diagnosed with – and dying from – prostate cancer compared with white men, according to a study by Public Health England and Prostate Cancer UK.
MERS causes only mild symptoms in monkeys, so although the vaccine seemed to reduce their symptoms, it's hard to know if this will apply to humans as well
The World Health Organisation is doing its final checks and could declare Nigeria officially free of polio by September. Somalia could be next
Researchers in Hong Kong have cured infected monkeys of MERS using existing drugs
European Medicines Agency recommends RTS,S, or Mosquirix, developed by GSK and backed by Gates Foundation, for use in young children in Africa